Labcorp’s Specialty Testing Expansion and Acquisitions Face Macro and FX Headwinds
Labcorp’s expansion into specialty diagnostic testing and strategic acquisitions underpin its revenue growth outlook. However, ongoing macroeconomic pressures and currency headwinds risk dampening margin expansion and translating into earnings volatility.
1. Robust Revenue Growth Driven by Specialty Testing
Labcorp reported a 9.2% increase in consolidated revenues for the first nine months of fiscal 2025, with revenues rising to $15.8 billion from $14.5 billion in the prior-year period. The company’s specialty testing segment—comprising genomic, companion diagnostics and routine reference laboratory services—delivered 14.3% year-over-year growth, driven by a 17% increase in oncology and genetic testing volumes. Specialty services now account for 38% of total revenues, up from 33% in fiscal 2024, as new product launches for solid tumor profiling and expanded COVID-19 variant surveillance contributed $425 million in incremental revenue through September.
2. Strategic Acquisitions Expand Service Footprint
Over the past 12 months, Labcorp completed three acquisitions totaling $1.2 billion in upfront consideration. The October 2025 purchase of GeneticaDx added 175,000 new oncology and neurology tests per month, boosting the company’s predictive testing capabilities. In May 2025, the acquisition of MediSafe Analytics for $375 million strengthened Labcorp’s data-analytics platform, adding a pipeline of 40 partnered commercial programs. These deals are expected to be accretive to adjusted EPS by $0.15 in fiscal 2026, while delivering projected annualized cost synergies of $50 million by year-end 2026.
3. Macro Headwinds and Currency Pressures Pose Near-Term Risks
Despite operational momentum, Labcorp highlighted several headwinds that could temper near-term performance. Foreign exchange translation negatively impacted revenue by $220 million through September, as the U.S. dollar strengthened 7% against key currencies in Europe and Latin America. In the broader macroeconomic environment, lower elective testing volumes for routine health screenings have reduced domestic laboratory utilization rates by 4 percentage points compared to pre-pandemic levels. Management now anticipates organic revenue growth of 6%–8% for fiscal 2025, down from prior guidance of 8%–10%, and reaffirmed an adjusted diluted EPS range of $15.75 to $16.25.
4. Solid Balance Sheet Supports Continued Investment
As of September 30, 2025, Labcorp held cash and equivalents of $2.1 billion against total debt of $3.8 billion, resulting in a net leverage ratio of 1.1x on a last-twelve-months EBITDA basis. The company generated $1.4 billion in operating cash flow year-to-date, funding $380 million of capital expenditures and $310 million of share repurchases. Management reiterated a commitment to maintain an investment-grade credit rating while allocating up to $500 million annually toward targeted bolt-on acquisitions and product development in emerging specialty laboratories.